Significant capital is being invested in artificial intelligence for drug discovery processes, promising to revolutionize biological identification and optimization. Companies need to prepare for increased productivity through AI-driven discovery, potentially reducing the timeline for drug development. Challenges such as costly clinical trials, delayed commercialization, and limited drug lifecycles can be addressed by AI, which streamlines trials, enhances cross-discipline workflows, and uncovers new drug applications. This technological shift improves efficiency, profitability, and speeds up the delivery of innovative therapies to patients, offering significant advancements in the pharmaceutical industry. AI expert Dave Latshaw II bridges biotechnology and AI to address complex challenges in research and development.
Source link
Overcoming Pharma’s Major Pain Points and Pitfalls With AI
